277 related articles for article (PubMed ID: 12134269)
1. Role of upper and lower respiratory tract immunity in resistance to Mycoplasma respiratory disease.
Hodge LM; Simecka JW
J Infect Dis; 2002 Jul; 186(2):290-4. PubMed ID: 12134269
[TBL] [Abstract][Full Text] [Related]
2. Combined oral/nasal immunization protects mice from Sendai virus infection.
Nedrud JG; Liang XP; Hague N; Lamm ME
J Immunol; 1987 Nov; 139(10):3484-92. PubMed ID: 2824609
[TBL] [Abstract][Full Text] [Related]
3. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
[TBL] [Abstract][Full Text] [Related]
4. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
Hickey DK; Aldwell FE; Beagley KW
Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection.
Skelding KA; Hickey DK; Horvat JC; Bao S; Roberts KG; Finnie JM; Hansbro PM; Beagley KW
Vaccine; 2006 Jan; 24(3):355-66. PubMed ID: 16153755
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background.
Sutton P; Doidge C; Pinczower G; Wilson J; Harbour S; Swierczak A; Lee A
FEMS Immunol Med Microbiol; 2007 Jul; 50(2):213-9. PubMed ID: 17567282
[TBL] [Abstract][Full Text] [Related]
7. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization.
Yang X; Walters N; Robison A; Trunkle T; Pascual DW
Vaccine; 2007 Mar; 25(12):2261-8. PubMed ID: 17239499
[TBL] [Abstract][Full Text] [Related]
8. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
Nyström-Asklin J; Adamsson J; Harandi AM
Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
[TBL] [Abstract][Full Text] [Related]
9. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
Akhiani AA; Stensson A; Schön K; Lycke N
Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
[TBL] [Abstract][Full Text] [Related]
10. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K
Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585
[TBL] [Abstract][Full Text] [Related]
11. Diversity of mucosal immune responses in upper respiratory organs and its application for mucosal vaccine.
Kurono Y; Miyashita K; Makise T; Nagano H
Adv Otorhinolaryngol; 2011; 72():146-8. PubMed ID: 21865715
[TBL] [Abstract][Full Text] [Related]
12. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
[TBL] [Abstract][Full Text] [Related]
13. Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant.
Saito M; Otake S; Ohmura M; Hirasawa M; Takada K; Mega J; Takahashi I; Kiyono H; McGhee JR; Takeda Y; Yamamoto M
J Infect Dis; 2001 Mar; 183(5):823-6. PubMed ID: 11181162
[TBL] [Abstract][Full Text] [Related]
14. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
[TBL] [Abstract][Full Text] [Related]
15. Effects of active and passive immunization on Mycoplasma pulmonis-induced pneumonia in mice.
Taylor G; Taylor-Robinson D
Immunology; 1976 May; 30(5):611-8. PubMed ID: 1278933
[TBL] [Abstract][Full Text] [Related]
16. Blinded, controlled field trial of two commercially available Mycoplasma bovis bacterin vaccines in veal calves.
Soehnlen MK; Aydin A; Lengerich EJ; Houser BA; Fenton GD; Lysczek HR; Burns CM; Byler LI; Hattel AL; Wolfgang DR; Jayarao BM
Vaccine; 2011 Jul; 29(33):5347-54. PubMed ID: 21664397
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.
Hodge LM; Marinaro M; Jones HP; McGhee JR; Kiyono H; Simecka JW
Infect Immun; 2001 Apr; 69(4):2328-38. PubMed ID: 11254590
[TBL] [Abstract][Full Text] [Related]
18. Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract.
Sanders MT; Deliyannis G; Pearse MJ; McNamara MK; Brown LE
Vaccine; 2009 Apr; 27(18):2475-82. PubMed ID: 19368789
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae.
Rodríguez A; Rottenberg M; Tjärnlund A; Fernández C
Scand J Immunol; 2006 Mar; 63(3):177-83. PubMed ID: 16499570
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and type of immune response following intranasal and subcutaneous immunisation of calves.
Rebelatto MC; Siger L; Hogenesch H
Res Vet Sci; 2001 Aug; 71(1):9-15. PubMed ID: 11666140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
